Jennifer Ferrell
Internal Medicine · Stillwater, OKNPI 1902860406
Payments from drug & device makers
Across 292 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Otsuka America Pharmaceutical, Inc.$767
- Bayer$459
- GSK$307
- Novo Nordisk$294
- Pfizer$293
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$3004%
- Travel & lodging$7139%
- Food & beverage$6,74987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $2,838 |
| Otsuka America Pharmaceutical, Inc. | 36 | $767 |
| Bayer | 27 | $459 |
| GSK | 18 | $307 |
| Novo Nordisk | 18 | $294 |
| Pfizer | 13 | $293 |
| Lilly USA, LLC | 18 | $274 |
| AstraZeneca(2 entities) | 13 | $218 |
| Lundbeck LLC | 8 | $202 |
| AbbVie | 9 | $199 |
| Amgen | 12 | $199 |
| Medtronic(2 entities) | 2 | $189 |
| Merck | 12 | $178 |
| SK Life Science, Inc. | 2 | $169 |
| Boehringer Ingelheim | 8 | $142 |
| Idorsia Pharmaceuticals US Inc | 6 | $112 |
| Harmony Biosciences LLC | 4 | $106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $94 |
| Johnson & Johnson | 4 | $83 |
| Eisai Inc. | 4 | $79 |
| Dexcom, Inc. | 4 | $75 |
| Insulet Corporation | 4 | $74 |
| Astellas Pharma US Inc | 3 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Edwards Lifesciences | 1 | $47 |
| Boston Scientific | 1 | $30 |
| Halozyme Inc | 1 | $29 |
| Nevro Corp. | 1 | $23 |
| UCB, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$1,389
- ACTIVA$167
- INFINITY$124
- Cenobamate$119
How this compares
$7,762 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $30,353 |
| FarxigaDapagliflozin Propanediol | 18 | $13,646 |
| MounjaroTirzepatide | 13 | $12,479 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $12,134 |
| GemtesaVibegron | 23 | $10,749 |
| OsphenaOspemifene | 12 | $2,826 |
| Potassium Chloride | 14 | $1,918 |
| Gabapentin | 82 | $929 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $858 |
| Oxycodone Hcl | 21 | $789 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $696 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $639 |
| Levothyroxine Sodium | 75 | $636 |
| Morphine Sulfate | 12 | $601 |
| Losartan Potassium | 42 | $588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $293 | $30,35327 claims |
| AstraZenecaFarxiga | $218 | $13,64618 claims |
| Lilly USA, LLCMounjaro | $274 | $12,47913 claims |
| GSKTrelegy Ellipta | $307 | $12,13415 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $63675 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Stillwater
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.